In a patient with myelofibrosis receiving a JAK inhibitor who presents to the emergency department with a hemoglobin of 5.8 g/dL and platelets below 10 × 10⁹/L, what is the recommended management, including use of growth‑factor agents?

Emergency Management of Severe Cytopenias in Myelofibrosis on JAK Inhibitor

Immediately hold the JAK inhibitor, transfuse packed red blood cells and platelets urgently, and do NOT use growth factor stimulators (erythropoietin or thrombopoietin receptor agonists) in this acute setting.

Immediate Actions

This patient presents with life-threatening cytopenias (hemoglobin 5.8 g/dL and platelets <10 × 10⁹/L) while on a JAK inhibitor. The priority is preventing hemorrhagic complications and addressing symptomatic anemia:

JAK Inhibitor Management

• Interrupt the JAK inhibitor immediately 1. The NCCN guidelines explicitly state that thrombocytopenia and anemia should be managed by dose interruption at the clinician's discretion based on clinical parameters 1.
• Do NOT taper the JAK inhibitor in this scenario—the guidelines specify tapering is only considered "for reasons other than thrombocytopenia or neutropenia" 1. With platelets <10 × 10⁹/L, abrupt discontinuation is appropriate.

Transfusion Support

• Transfuse packed red blood cells to address severe symptomatic anemia (hemoglobin 5.8 g/dL) 1
• Transfuse platelets given the critical thrombocytopenia (<10 × 10⁹/L) and high bleeding risk 1
• The guidelines explicitly state "platelet transfusions may be necessary" and "management of anemia may require blood transfusions" 1

Growth Factor Stimulators: NOT Recommended

Growth factors have no role in this acute emergency setting:

Erythropoietin-Stimulating Agents (ESAs)

• ESAs are ineffective in transfusion-dependent myelofibrosis patients 2
• The European LeukemiaNet guidelines note "a low rate of response to epoetins is expected" in transfusion-dependent patients, making "the risk/benefit of therapeutic use with epoetins questionable" 2
• ESAs are considered for chronic anemia management in non-transfusion-dependent patients, not acute crises

Thrombopoietin Receptor Agonists

• Not mentioned in any guideline for myelofibrosis-associated thrombocytopenia
• No evidence base for use in this disease context
• The focus remains on managing the underlying JAK inhibitor toxicity

Subsequent Management Algorithm

Once the patient is stabilized:

1. Monitor CBC every 2-4 weeks until parameters recover 1

2. Reassess JAK inhibitor therapy:

   • If platelets recover to 50-100 × 10⁹/L: Consider restarting at 5 mg twice daily 1
   • If platelets remain <50 × 10⁹/L: JAK inhibitor contraindicated with current agents (ruxolitinib, fedratinib)
   • Consider pacritinib specifically—this agent does not induce significant thrombocytopenia and maintains spleen response 3

3. For chronic anemia management (after acute crisis resolves):

   • Androgens (avoid if prostate or liver disease) 2
   • Danazol or prednisone 2
   • Lenalidomide if del(5q31) present 2
   • Thalidomide analogs (avoid if peripheral neuropathy grade ≥2) 2
   • Consider momelotinib as alternative JAK inhibitor—improves anemia and transfusion independence 4, 5, 6

Critical Pitfalls to Avoid

• Do not continue the JAK inhibitor at any dose with platelets <10 × 10⁹/L—this invites catastrophic bleeding
• Do not taper in this scenario despite general recommendations about withdrawal symptoms
• Do not use ESAs in transfusion-dependent patients—they are futile and delay appropriate management
• Do not delay transfusions while attempting other interventions—this patient needs immediate hematologic support

Long-Term Considerations

If the patient requires ongoing JAK inhibitor therapy but cannot tolerate standard agents due to cytopenias, pacritinib is the preferred option for severe thrombocytopenia (platelets <50 × 10⁹/L) 3, while momelotinib is preferred for significant anemia (hemoglobin <10 g/dL) with demonstrated transfusion independence benefits 4, 5, 6, 7.